ZURA | Zura Bio Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7450 - 1.8100
52 Week Range	1.7450 - 6.35
Beta	0.56
Implied Volatility	321.86%
IV Rank	70.85%
Day's Volume	277,854
Average Volume	476,296
Shares Outstanding	65,293,530
Market Cap	116,875,419
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-03-21

Valuation
Profitability
Growth
Health
P/E Ratio	-4.59
Forward P/E Ratio	N/A
EPS	-0.39
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	14
Country	USA
Website	ZURA

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

ZURA's peers: ABSI, ADPT, ALLR, ALT, ANNX, ARDX, ATNF, BNTC, CNTX, CRBP, CYTO, DRMA, DRUG, ELEV, ENSC, ENVB, EVAX, FGEN, GERN, GOVX, HEPA, HOTH, IMMP, INAB, CYBN, IPA, JAGX, LEXX, LPCN, MEIP, NBTX, NBY, NCNA, NERV, OCGN, ORMP, PALI, PHIO, PSTV, PYPD, PYXS, REVB, RIGL, RNAZ, SLS, SMMT, SNGX, TCBP, VTVT, VYNE, XBIO, CDIO, ERNA, SPRY, ZVSA, OCEA, CARM

*Chart delayed

Analyzing fundamentals for ZURA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ZURA Fundamentals page.

Watching at ZURA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ZURA Technicals page.